Heterogeneity of Randomized Controlled Trials of Fecal Microbiota Transplantation in Recurrent Clostridioides difficile Infection
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-2568
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Heterogeneity of Randomized Controlled Trials of Fecal Microbiota Transplantation in Recurrent Clostridioides difficile Infection ; day:18 ; month:7 ; year:2021 ; pages:1-8
Digestive diseases and sciences ; (18.7.2021), 1-8
- Urheber
-
Feuerstadt, Paul
Aroniadis, Olga C.
Svedlund, Felicia L.
Garcia, Mariana
Stong, Laura
Boules, Mena
Khanna, Sahil
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10620-021-07141-9
- URN
-
urn:nbn:de:101:1-2021102119361953160806
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:20 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Feuerstadt, Paul
- Aroniadis, Olga C.
- Svedlund, Felicia L.
- Garcia, Mariana
- Stong, Laura
- Boules, Mena
- Khanna, Sahil
- SpringerLink (Online service)
Ähnliche Objekte (12)
Fecal Microbiota Transplantation Is Effective for Postcolectomy Recurrent Clostridioides difficile Infection
Editorial: Rejuvenating the Microbiome in Recurrent Clostridioides difficile Infection with Fecal Microbiota Transplant
Applications of Fecal Microbiota Transplantation: Emphasis on Clostridioides difficile Infections
Budget Impact Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) for Preventing Recurrent Clostridioides difficile Infection in the US
Fecal microbiota composition is a better predictor of recurrent Clostridioides difficile infection than clinical factors in a prospective, multicentre cohort study
Oral, frozen fecal microbiota transplant (FMT) capsules for recurrent Clostridium difficile infection
Microbiota-Based Therapeutics as New Standard-of-Care Treatment for Recurrent Clostridioides difficile Infection
Journal Summary: Microbiome-Based Therapies for Recurrent Clostridioides difficile
Fecal Microbiota Transplantation May Be the Best Option in Treating Multiple Clostridioides difficile Infection: A Network Meta-Analysis
A Multi-Factorial Observational Study on Sequential Fecal Microbiota Transplant in Patients with Medically Refractory Clostridioides difficile Infection
Microbiota-based markers predictive of development of Clostridioides difficile infection
Cost-Effectiveness Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) Versus Standard of Care for the Prevention of Recurrent Clostridioides difficile Infection in the USA
Fecal Microbiota Transplantation Is Effective for Postcolectomy Recurrent Clostridioides difficile Infection
Editorial: Rejuvenating the Microbiome in Recurrent Clostridioides difficile Infection with Fecal Microbiota Transplant
Applications of Fecal Microbiota Transplantation: Emphasis on Clostridioides difficile Infections
Budget Impact Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) for Preventing Recurrent Clostridioides difficile Infection in the US
Fecal microbiota composition is a better predictor of recurrent Clostridioides difficile infection than clinical factors in a prospective, multicentre cohort study
Oral, frozen fecal microbiota transplant (FMT) capsules for recurrent Clostridium difficile infection
Microbiota-Based Therapeutics as New Standard-of-Care Treatment for Recurrent Clostridioides difficile Infection
Journal Summary: Microbiome-Based Therapies for Recurrent Clostridioides difficile
Fecal Microbiota Transplantation May Be the Best Option in Treating Multiple Clostridioides difficile Infection: A Network Meta-Analysis
A Multi-Factorial Observational Study on Sequential Fecal Microbiota Transplant in Patients with Medically Refractory Clostridioides difficile Infection
Microbiota-based markers predictive of development of Clostridioides difficile infection
Cost-Effectiveness Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) Versus Standard of Care for the Prevention of Recurrent Clostridioides difficile Infection in the USA
Fecal Microbiota Transplantation Is Effective for Postcolectomy Recurrent Clostridioides difficile Infection
Editorial: Rejuvenating the Microbiome in Recurrent Clostridioides difficile Infection with Fecal Microbiota Transplant
Applications of Fecal Microbiota Transplantation: Emphasis on Clostridioides difficile Infections
Budget Impact Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) for Preventing Recurrent Clostridioides difficile Infection in the US
Fecal microbiota composition is a better predictor of recurrent Clostridioides difficile infection than clinical factors in a prospective, multicentre cohort study
Oral, frozen fecal microbiota transplant (FMT) capsules for recurrent Clostridium difficile infection
Microbiota-Based Therapeutics as New Standard-of-Care Treatment for Recurrent Clostridioides difficile Infection
Journal Summary: Microbiome-Based Therapies for Recurrent Clostridioides difficile
Fecal Microbiota Transplantation May Be the Best Option in Treating Multiple Clostridioides difficile Infection: A Network Meta-Analysis
A Multi-Factorial Observational Study on Sequential Fecal Microbiota Transplant in Patients with Medically Refractory Clostridioides difficile Infection
Microbiota-based markers predictive of development of Clostridioides difficile infection